Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.

Authors

Kim N Chi
Neil Fleshner
Vincenzo Emanuele Chiuri
Siska Van Bruwaene
Jason Hafron, Beaumont Health
Douglas G McNeel
Peter De Porre
Raymond Scott Maul
Mahesh Daksh
Xiaogang Zhong

Document Type

Article

Publication Date

5-8-2023

Publication Title

The Oncologist

Abstract

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

Volume

28

Issue

5

First Page

309

Last Page

309

Recommended Citation

Chi KN, Fleshner N, Chiuri VE, Van Bruwaene S, Hafron J, McNeel DG, De Porre P, Maul RS, Daksh M, Zhong X, Mason GE, Tutrone RF. Niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: Phase II QUEST Study results. Oncologist. 2023 May 8;28(5):e309-e312. doi: 10.1093/oncolo/oyad008. PMID: 36994854.

DOI

10.1093/oncolo/oyad008

ISSN

1549-490X

PubMed ID

36994854